Recognition of extraordinary loss (impairment loss)
株式会社PRISM BioLab (reporting company)
Facilities and other assets newly installed during the fourth quarter accounting period of the fiscal year ending September 2026
The carrying amount was reduced to its recoverable amount from the perspective of business profitability. This resulted from capital investment to expand research and development functions, representing proactive upfront investment necessary to expand the Company's proprietary development and collaborative development businesses.
¥48.864 million (extraordinary loss; impairment loss). Cumulative amount for the fiscal year: ¥92.129 million (extraordinary loss; impairment loss)
Fourth quarter accounting period of the fiscal year ending September 2026 (1 July 2026 to 30 September 2026). The cumulative amount was recorded in the fiscal year (1 October 2025 to 30 September 2026).
| Item | Details |
|---|---|
| Event name | Recognition of extraordinary loss (impairment loss) |
| Date of occurrence | Recorded in the fourth quarter accounting period of the fiscal year ending September 2026 (1 July 2026 to 30 September 2026). The specific date of occurrence is Not disclosed. |
| Subject Entity | 株式会社PRISM BioLab (reporting company) |
| Target Locations / Products | Facilities and other assets newly installed during the fourth quarter accounting period of the fiscal year ending September 2026 |
| Cause | The carrying amount was reduced to its recoverable amount from the perspective of business profitability. This resulted from capital investment to expand research and development functions, representing proactive upfront investment necessary to expand the Company's proprietary development and collaborative development businesses. |
| Amount of Impact on Business Performance | ¥48.864 million (extraordinary loss; impairment loss). Cumulative amount for the fiscal year: ¥92.129 million (extraordinary loss; impairment loss) |
| Accounting period in which recognized | Fourth quarter accounting period of the fiscal year ending September 2026 (1 July 2026 to 30 September 2026). The cumulative amount was recorded in the fiscal year (1 October 2025 to 30 September 2026). |
Items this document does not state (18)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This resulted from capital investment to expand research and development functions, representing proactive upfront investment necessary to expand the Company's proprietary development and collaborative development businesses.